Adaptive Pemafibrate Dosing Regimens for Specialized Patient Populations

The present inventive concept discloses novel pemafibrate dosing regimens tailored to specific, high-need patient populations, such as those residing in high-altitude regions, with compromised liver function, diabetes, undergoing hemodialysis, or exposed to extreme temperatures.

The original patent disclosed pemafibrate dosing regimens for general dyslipidemia treatment. However, certain patient populations require adapted dosing regimens to mitigate specific health risks or complications. The present inventive concept addresses these limitations by providing specialized pemafibrate dosing regimens for niche patient populations.

The inventive concept comprises four distinct pemafibrate dosing regimens, each tailored to a specific patient population. The first regimen involves administering pemafibrate at an adjusted daily dose ranging from 0.1 mg to 0.2 mg, in conjunction with an OATP1B inhibitor, to mitigate altitude-induced hypoxia in patients residing in high-altitude regions. The second regimen co-administers pemafibrate with a hepatic enzyme inducer to enhance the efficacy of pemafibrate in patients with compromised liver function. The third regimen combines pemafibrate or a pharmaceutically acceptable salt thereof with a sulfonylurea to synergistically improve glucose metabolism and lipid profiles in patients with diabetes. The fourth regimen involves administering pemafibrate at an adjusted daily dose ranging from 0.1 mg to 0.2 mg, in conjunction with a thermoregulatory agent, to mitigate temperature-induced metabolic stress in patients exposed to extreme temperatures. A fifth regimen involves co-administering pemafibrate with a phosphate binder to reduce the risk of cardiovascular events in patients undergoing hemodialysis.

The inventive concept's novelty lies in the adaptation of pemafibrate dosing regimens to specific, high-need patient populations, which is not addressed in the original patent. The inventive step involves the combination of pemafibrate with specific agents or inhibitors tailored to each patient population, resulting in improved efficacy and safety.

Alternative embodiments of the inventive concept could include the use of different PPARα activators or other lipid-lowering agents, or the development of novel formulations or delivery systems tailored to each patient population. Variations could also include the adaptation of the dosing regimens to other patient populations with unique needs or health risks.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of dyslipidemia treatment, high-altitude medicine, liver disease management, diabetes care, and nephrology. The target markets include pharmaceutical companies, hospitals, and specialized clinics catering to these patient populations.